Lonza Group Continues To Leverage Biopharma's Optimization Push
Source: SeekingAlpha
2026-01-29 12:17:19 ET
More and more it feels like companies across industries have bought into the idea that it is often best to specialize in whatever it is they do best and outsource as much of what remains as is practical. In the case of pharmaceutical and biotech companies (“biopharma” from here on), companies have increasingly adopted the view that their expertise is in R&D and/or marketing, and manufacturing is a cost center where the risk/reward is skewed toward more things going wrong than adding benefits....
Read the full article on Seeking Alpha
For further details see:
Lonza Group Continues To Leverage Biopharma's Optimization Push
Lonza Group AG
NASDAQ: LZAGF
LZAGF Trading
1.85% G/L:
$714.96 Last:
54 Volume:
$714.96 Open:
